Alpern Robert J 4

What Happened

• Robert J. Alpern, a director of Abbott Laboratories, received a grant of 76 stock-equivalent shares (reported as a derivative award) on 2026-03-31. The grant is reported at $102.67 per share, for a total reported value of $7,803. This was not an open-market purchase or sale but a compensation-related award.

Key Details

• Transaction date: 2026-03-31
• Transaction type/code: Award/Grant (A) — derivative (stock-equivalent units)
• Price/value: $102.67 per share; total value $7,803
• Shares owned after transaction: Not specified in this filing
• Filing date: 2026-04-02 — filed within the Form 4 two-business-day window (timely)
• Footnotes:
  • F1: These are director fees credited to a stock-equivalent unit account in a grantor trust; units earn returns as if invested in Abbott shares and are generally paid in cash at age 65 or upon retirement from the board.
  • F2: The reported balance includes stock-equivalent units acquired via dividend reinvestment.

Context

• This is a routine director compensation award (stock-equivalent units) rather than a market buy or sell. Stock-equivalent units are typically paid in cash later and are not immediately tradable shares, so the transaction should be viewed as compensation reporting, not an explicit market sentiment signal.